New manufacturing method for therapeutic cells
| Reference number | |
| Coordinator | Nyctea Technologies AB |
| Funding from Vinnova | SEK 1 057 987 |
| Project duration | November 2023 - June 2025 |
| Status | Completed |
| Venture | Competence centre |
Important results from the project
We achieved the project´s main objective, which was to develop the first cell separator that uses electrochemistry to separate cells in the cell culture process. Several ambitious sub-goals remain to be achieved. However, during the course of the project, a lot of useful data was produced that we can use in follow-up projects in partnership with existing and new industrial partners.
Expected long term effects
There is great potential to apply this groundbreaking technology in future products for manufacturing cell therapies. The cost can thus be reduced and more patients can have access to the best cell-based medicines. The project can help Nyctea to consolidate its technology as biocompatible which can pave the way for more applications and products in contact with living tissue medtech, drug-delivery for example.
Approach and implementation
The implementation of the project was characterized by the need for a good source of cell culture on which we could conduct tests. Unlike biomolecules (such as Nyctea), cells require a sterile environment, which was a challenge to access. Thanks to good cooperation within our consortium, we managed to secure a good supply of sample material and a suitable cell line to conduct basic tests on. However, it took a little longer to set up than we had planned and affected the schedule slightly.